FDA NGS & CRISPR Guidance

Gene editing works like molecular find-and-replace: tools such as CRISPR cut or rewrite DNA, and regulators want proof they did not hit the wrong address. On April 14, the Food and Drug Administration issued draft guidance telling companies how to use next-generation sequencing to check that risk before human trials. (fda.gov) The new document is titled *Safety Assessment of Genome Editing in Human Gene Therapy Products Using Next-Generation Sequencing* and the agency says it covers nonclinical studies that will likely be needed to start clinical trials of investigational genome-editing products. FDA posted the draft in April 2026 and set a public comment deadline of July 14, 2026. (fda.gov) Next-generation sequencing is a high-volume DNA readout, and FDA said sponsors should use it with bioinformatics software to look for off-target editing and loss of genome integrity, including chromosomal damage. The agency said the recommendations are meant to support both Investigational New Drug applications and Biologics License Applications. (fda.gov) FDA said the draft applies to ex vivo products, where cells are edited outside the body, and in vivo products, where editing happens directly in a patient’s tissues. The agency also said the document gives specific recommendations on sequencing strategies, sample selection, analysis parameters, and reporting. (fda.gov) This April draft did not arrive on its own. FDA said it builds on the agency’s January 2024 guidance on human gene therapy products incorporating genome editing, which already told sponsors to address off-target editing, unintended on-target effects, and long-term follow-up. (fda.gov) A second FDA draft from February 2026 set the broader policy frame for individualized therapies aimed at specific genetic conditions with a known biological cause. FDA said that “plausible mechanism” framework is meant to help developers generate enough safety and effectiveness evidence for therapies built for very small patient groups. (fda.gov) In plain terms, the February framework addresses how a company can argue that a therapy aimed at one mutation should work for another closely related mutation without running a full conventional program for every variant. FDA said the framework covers the clinical, nonclinical, and chemistry, manufacturing, and controls data needed to support approval or licensure of an individualized therapy for a specific indication. (fda.gov) FDA tied the April sequencing draft directly to that February push for ultra-rare diseases. In its April 14 announcement, the agency said the safety guidance supports the individualized-therapy framework it launched in February. (fda.gov) The agency has been moving in this direction for several years. FDA held a public workshop in December 2022 on genetic heterogeneity and off-target editing, then finalized its broader human genome-editing guidance in January 2024 before adding the sequencing-specific draft in April 2026. (fda.gov) One claim circulating online is that FDA set a 50-base-pair threshold for off-target review and opened a path to modular approvals without new trials. FDA’s public pages for the April and February drafts confirm the new guidances and their scope, but I could not verify that specific 50-base-pair standard or a no-new-trials approval rule from the accessible FDA source text available here. (fda.gov)